BerGenBio

Board/Management Information • Nov 20, 2024

BerGenBio Appoints Olav Hellebø as CEO

BerGenBio Appoints Olav Hellebø as CEO

Bergen, Norway, November 20, 2024 - BerGenBio ASA (OSE: BGBIO), a clinical-stage

biopharmaceutical company developing novel, selective AXL kinase inhibitors for

severe unmet medical needs, announced today the appointment of Olav Hellebø as

CEO. Mr. Hellebø will assume the position on November 21, 2024.

Mr. Hellebø brings three decades of experience in the pharmaceutical and

biotechnology industries. Since 2023, he has served as board director in the

clinical stage immuno-oncology company Cytovation ASA, and since 2021 he has

been a board director at the clinical stage biopharmaceutical company, Antev

Ltd, specializing in urology and oncology treatments. Prior to this, Mr.

Hellebø's experience includes the role as CEO of ReNeuron Group PLC, a UK-based

clinical-stage company specializing in cell therapy for ophthalmic and neurology

-related diseases, and CEO at Clavis Pharma ASA, an oncology-focused biotech

company traded at the Oslo Stock Exchange. Mr Hellebø's earlier career includes

leadership roles at UCB-Celltech, Novartis UK, and at Schering-Plough (now part

of Merck & Co.).

"BerGenBio is at the forefront of exploring highly selective AXL inhibition as a

therapeutic enhancement for the large number of patients with non-squamous non

-small cell lung cancer with mutations in the STK11 gene. I am thrilled to join

the company and look forward to collaborating with the board and team to advance

the candidate drug, bemcentinib, through the next stages of clinical development

and to take BerGenBio to the next phase", said Olav Hellebø.

"Mr. Hellebø brings a wealth of experience as a leader in pharmaceutical and

biotechnology companies, with a strong track record of success. His extensive

expertise in leading biotech companies, raising capital, and securing

partnership deals makes him exceptionally well-suited to guide BerGenBio and to

execute on our focused strategy to study STK11m NSCLC patients in our on-going

Ph1b/2a BGBC016 trial", said Chairman of the Board, Anders Tullgren.

Contacts

Anders Tullgren, Chair of the Board, BerGenBio ASA

ir@bergenbio.com

Rune Skeie, CFO, BerGenBio ASA

rune.skeie@bergenbio.com

Jan Lilleby, Media Relations, BerGenBio ASA

jl@lillebyfrisch.no

About BerGenBio ASA

BerGenBio is a clinical-stage biopharmaceutical company focused on developing

transformative drugs targeting AXL as a potential cornerstone of therapy for

aggressive diseases, including cancer and severe respiratory infections. The

Company is focused on its proprietary lead candidate, bemcentinib, a potentially

first-in-class selective AXL inhibitor in development for STK11 mutated NSCLC

and severe respiratory infections. BerGenBio is based in Bergen, Norway with a

subsidiary in Oxford, UK. The company is listed on the Oslo Stock Exchange

(ticker: BGBIO). For more information, visitwww.bergenbio.com

This information is subject to the disclosure requirements pursuant to section 5

-12 of the Norwegian Securities Trading Act.